Ticagrelor use in patients after percutaneous coronary intervention: one year follow up in a community hospital.

IF 1.3

American journal of cardiovascular disease Pub Date : 2022-06-15 eCollection Date: 2022-01-01

Sarath Lal Mannumbeth Renjithlal, Mohamed Magdi, Keerthi Renjith, Mostafa Reda Mostafa, Musaib Syed, Fahd Shaukat, Viqarunnisa Zahid, Nathan Ritter

{"title":"Ticagrelor use in patients after percutaneous coronary intervention: one year follow up in a community hospital.","authors":"Sarath Lal Mannumbeth Renjithlal, Mohamed Magdi, Keerthi Renjith, Mostafa Reda Mostafa, Musaib Syed, Fahd Shaukat, Viqarunnisa Zahid, Nathan Ritter","doi":"","DOIUrl":null,"url":null,"abstract":"Background: Current guidelines from American College of Cardiology (ACC) recommend ticagrelor over clopidogrel in patients with acute coronary syndrome. We have observed many patients being switched from ticagrelor to clopidogrel after percutaneous coronary intervention (PCI) in our hospital. Our goal is to evaluate the use rate of ticagrelor and categorize the reasons for non-use.Methods: We performed a retrospective data analysis of all patients who underwent PCI at Unity Hospital of Rochester, New York, from January 2019 to January 2020. A total of 330 patients underwent PCI for ACS over the year. After exclusions, 277 patients were enrolled in the analysis.Results: Of the 277 patients, 179 (65%) completed one year of ticagrelor therapy, and 98 (35%) stopped ticagrelor and transitioned to clopidogrel. The most common reason for switching from ticagrelor was dyspnea (42 patients), followed by cost concerns (41 patients).Conclusion: At our community hospital, completion of one-year use of ticagrelor post-PCI occurred in 65% of patients. The most common reasons for discontinuation are dyspnea and medication cost.","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"12 3","pages":"143-148"},"PeriodicalIF":1.3000,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301028/pdf/ajcd0012-0143.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cardiovascular disease","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Current guidelines from American College of Cardiology (ACC) recommend ticagrelor over clopidogrel in patients with acute coronary syndrome. We have observed many patients being switched from ticagrelor to clopidogrel after percutaneous coronary intervention (PCI) in our hospital. Our goal is to evaluate the use rate of ticagrelor and categorize the reasons for non-use.

Methods: We performed a retrospective data analysis of all patients who underwent PCI at Unity Hospital of Rochester, New York, from January 2019 to January 2020. A total of 330 patients underwent PCI for ACS over the year. After exclusions, 277 patients were enrolled in the analysis.

Results: Of the 277 patients, 179 (65%) completed one year of ticagrelor therapy, and 98 (35%) stopped ticagrelor and transitioned to clopidogrel. The most common reason for switching from ticagrelor was dyspnea (42 patients), followed by cost concerns (41 patients).

Conclusion: At our community hospital, completion of one-year use of ticagrelor post-PCI occurred in 65% of patients. The most common reasons for discontinuation are dyspnea and medication cost.

本刊更多论文

替格瑞洛在经皮冠状动脉介入治疗患者中的应用:社区医院一年随访

背景:目前美国心脏病学会(ACC)的指南推荐急性冠脉综合征患者使用替格瑞洛而不是氯吡格雷。我们观察到许多患者在我院经皮冠状动脉介入治疗(PCI)后由替格瑞洛转为氯吡格雷。我们的目标是评估替格瑞洛的使用率，并对不使用的原因进行分类。方法:我们对2019年1月至2020年1月在纽约州罗切斯特联合医院接受PCI治疗的所有患者进行回顾性数据分析。全年共有330例ACS患者接受了PCI治疗。排除后，277例患者纳入分析。结果:277例患者中，179例(65%)完成了一年的替格瑞洛治疗，98例(35%)停止替格瑞洛治疗，转而使用氯吡格雷。停用替格瑞洛最常见的原因是呼吸困难(42例)，其次是成本问题(41例)。结论:在我们的社区医院，65%的患者在pci术后完成了一年的替格瑞洛治疗。最常见的原因是呼吸困难和药物费用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cardiovascular disease CARDIAC & CARDIOVASCULAR SYSTEMS-

自引率

0.00%

发文量